Sommer WH, Ceelen F, Garcia-Albeniz X, Paprottka PM, Auernhammer CJ, Armbruster M, Nikolaou K, Haug AR, Reiser MF, Theisen D. Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin. Eur Radiol. 2013 Nov;23(11):3094-103. doi: 10.1007/s00330-013-2925-8
Woods MS, Kiri S, Ling CS, McCrink L, Zimovetz E, Hass B. A systematic review of economic evidence in hepatitis c: methods used in recent economic evaluations. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A579.
Woods MS, Kiri S, Ling CS, McCrink L, Zimovetz E, Hass B. A systematic review of economic evidence in hepatitis c: an overview of cost, utility, and cost-effectiveness data. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A349.
Ainsworth C, Kiri S, Ling CS, Heyes AE, Hass B. The global burden, incidence, and prevalence of chronic hepatitis c. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A342.
Younossi ZM, Gordon SC, Saab S, Ahmed A, Brogan A, Cure S. A decision-analytic Markov model to evaluate the health outcomes of sofosbuvir for previously untreated patients with chronic hepatitis C virus genotype 1 infection. Poster presented at the American Association for the Study of Liver Diseases; November 1, 2013.
Younossi ZM, Saab S, Gordon SC, Ahmed A, Brogan A, Cure S. Evaluation of long-term health outcomes associated with earlier versus later initiation of treatment in previously untreated patients with chronic hepatitis C virus genotype 1 infection. Poster presented at the Annual Meeting of the American Association for the Study of Liver Diseases; November 1, 2013.